Results of an Early Access Treatment Protocol of Daratumumab Monotherapy in Spanish Patients With Relapsed or Refractory Multiple Myeloma

Daratumumab is a human CD38-targeted monoclonal antibody approved as monotherapy for heavily pretreated relapsed and refractory multiple myeloma. We report findings for the Spanish cohort of an open-label treatment protocol that provided early access to daratumumab monotherapy and collected safety a...

Descripción completa

Detalles Bibliográficos
Autores principales: Alegre, Adrián, de la Rubia, Javier, Sureda Balari, Anna, Encinas Rodríguez, Cristina, Suárez, Alexia, Blanchard, María Jesús, Bargay Lleonart, Joan, Rodríguez-Otero, Paula, Insunza, Andrés, Palomera, Luis, Peñarrubia, María Jesús, Ríos-Tamayo, Rafael, Casado Montero, Luis Felipe, González, Marta Sonia, Potamianou, Anna, Couturier, Catherine, Pei, Huiling, Hevia, Henar, Milionis, Iordanis, Gaudig, Maren, Mateos, María-Victoria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306316/
https://www.ncbi.nlm.nih.gov/pubmed/32647799
http://dx.doi.org/10.1097/HS9.0000000000000380

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306316/
https://www.ncbi.nlm.nih.gov/pubmed/32647799
http://dx.doi.org/10.1097/HS9.0000000000000380

Ejemplares similares